Shruthi Ravimohan1,2, Neo Tamuhla2, Kebatshabile Nfanyana2, Andrew P Steenhoff2,3,4, Rona Letlhogile2, Ian Frank1, Rob Roy MacGregor1, Robert Gross1,2,5, Drew Weissman1,2, Gregory P Bisson1,2,5. 1. Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania, Philadelphia. 2. Botswana-UPenn Partnership, Gaborone. 3. Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania. 4. Children's Hospital of Philadelphia. 5. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Abstract
BACKGROUND: The immunopathogenesis of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) remains unclear. We determined the association between pathogen-specific T-cell responses and development of paradoxical TB-IRIS on antiretroviral therapy (ART). METHODS: This study was nested within a prospective cohort study of HIV-infected patients with active pulmonary tuberculosis and baseline CD4 counts ≤125 cells/µL initiating ART. T-cell immune activation (CD38, HLA-DR, and PD-1 expression), phenotype, and polyfunctional pathogen-specific cellular immune responses prior to and 4 weeks after ART initiation were determined by flow cytometry. Patients with TB-IRIS were compared to non-IRIS controls using χ(2) and rank-sum tests and logistic regression. RESULTS: TB-IRIS patients and controls had similar CD4 counts, levels of T-cell-associated immune activation, frequencies of T-cell memory subsets, and frequencies of interferon gamma (IFN-γ(+))/interleukin 2 (IL-2(+))/tumor necrosis factor alpha (TNF-α(+)) CD4(+) T-cells prior to ART initiation. After ART initiation, cellular immune activation and T-cell subsets also were similar in TB-IRIS patients and controls. In contrast, TB-IRIS patients had significantly greater early increases in the frequency of tuberculosis-specific polyfunctional IFN-γ(+)/IL-2(+)/TNF-α(+) CD4(+) T-cells on ART (P = .02); each quartile increase in the percentage of these cells was independently associated with a 2.8-fold increased risk of TB-IRIS (95% confidence interval, 1.1 to 7.5-fold). In a secondary analysis, patients with TB-IRIS had rapid, concomitant increases in tuberculosis-specific adaptive immune responses and interleukin 6 (IL-6) levels, whereas controls with similarly rapid increases in cellular immune function had IL-6 levels that tended to decrease on ART. CONCLUSIONS: Rapid expansion of tuberculosis-specific polyfunctional CD4(+) T-cell responses, likely linked to increases in IL-6, is associated with development of paradoxical TB-IRIS.
BACKGROUND: The immunopathogenesis of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) remains unclear. We determined the association between pathogen-specific T-cell responses and development of paradoxical TB-IRIS on antiretroviral therapy (ART). METHODS: This study was nested within a prospective cohort study of HIV-infectedpatients with active pulmonary tuberculosis and baseline CD4 counts ≤125 cells/µL initiating ART. T-cell immune activation (CD38, HLA-DR, and PD-1 expression), phenotype, and polyfunctional pathogen-specific cellular immune responses prior to and 4 weeks after ART initiation were determined by flow cytometry. Patients with TB-IRIS were compared to non-IRIS controls using χ(2) and rank-sum tests and logistic regression. RESULTS:TB-IRIS patients and controls had similar CD4 counts, levels of T-cell-associated immune activation, frequencies of T-cell memory subsets, and frequencies of interferon gamma (IFN-γ(+))/interleukin 2 (IL-2(+))/tumor necrosis factor alpha (TNF-α(+)) CD4(+) T-cells prior to ART initiation. After ART initiation, cellular immune activation and T-cell subsets also were similar in TB-IRIS patients and controls. In contrast, TB-IRIS patients had significantly greater early increases in the frequency of tuberculosis-specific polyfunctional IFN-γ(+)/IL-2(+)/TNF-α(+) CD4(+) T-cells on ART (P = .02); each quartile increase in the percentage of these cells was independently associated with a 2.8-fold increased risk of TB-IRIS (95% confidence interval, 1.1 to 7.5-fold). In a secondary analysis, patients with TB-IRIS had rapid, concomitant increases in tuberculosis-specific adaptive immune responses and interleukin 6 (IL-6) levels, whereas controls with similarly rapid increases in cellular immune function had IL-6 levels that tended to decrease on ART. CONCLUSIONS: Rapid expansion of tuberculosis-specific polyfunctional CD4(+) T-cell responses, likely linked to increases in IL-6, is associated with development of paradoxical TB-IRIS.
Authors: R P Bucy; R D Hockett; C A Derdeyn; M S Saag; K Squires; M Sillers; R T Mitsuyasu; J M Kilby Journal: J Clin Invest Date: 1999-05-15 Impact factor: 14.808
Authors: J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom Journal: Immunity Date: 1995-06 Impact factor: 31.745
Authors: Philip M Grant; Lauren Komarow; Janet Andersen; Irini Sereti; Savita Pahwa; Michael M Lederman; Joseph Eron; Ian Sanne; William Powderly; Evelyn Hogg; Carol Suckow; Andrew Zolopa Journal: PLoS One Date: 2010-07-01 Impact factor: 3.240
Authors: Anne Bourgarit; Guislaine Carcelain; Valerie Martinez; Caroline Lascoux; Veronique Delcey; Brigitte Gicquel; Eric Vicaut; Philippe H Lagrange; Daniel Sereni; Brigitte Autran Journal: AIDS Date: 2006-01-09 Impact factor: 4.177
Authors: Bruno B Andrade; Amrit Singh; Gopalan Narendran; Melissa E Schechter; Kaustuv Nayak; Sudha Subramanian; Selvaraj Anbalagan; Stig M R Jensen; Brian O Porter; Lis R Antonelli; Katalin A Wilkinson; Robert J Wilkinson; Graeme Meintjes; Helen van der Plas; Dean Follmann; Daniel L Barber; Soumya Swaminathan; Alan Sher; Irini Sereti Journal: PLoS Pathog Date: 2014-10-02 Impact factor: 6.823
Authors: Graeme Meintjes; Katalin Andrea Wilkinson; Molebogeng Xheeda Rangaka; Keira Skolimowska; Kerryn van Veen; Musaed Abrahams; Ronnett Seldon; Dominique J Pepper; Kevin Rebe; Priscilla Mouton; Gilles van Cutsem; Mark Patrick Nicol; Gary Maartens; Robert John Wilkinson Journal: Am J Respir Crit Care Med Date: 2008-08-28 Impact factor: 21.405
Authors: Ngomu Akeem Akilimali; Daniel M Muema; Charles Specht; Christina C Chang; Mahomed-Yunus S Moosa; Stuart M Levitz; Sharon R Lewin; Martyn A French; Thumbi Ndungʼu Journal: J Acquir Immune Defic Syndr Date: 2019-04-15 Impact factor: 3.731
Authors: Anangi Balasiddaiah; Haleh Davanian; Soo Aleman; Anna Pasetto; Lars Frelin; Matti Sällberg; Volker Lohmann; Sarene Koh; Antonio Bertoletti; Margaret Chen Journal: J Virol Date: 2017-04-13 Impact factor: 5.103
Authors: Luxin Pei; Kiyoshi F Fukutani; Rafael Tibúrcio; Adam Rupert; Eric W Dahlstrom; Frances Galindo; Elizabeth Laidlaw; Andrea Lisco; Maura Manion; Bruno B Andrade; Irini Sereti Journal: Front Immunol Date: 2021-06-15 Impact factor: 7.561